Multicenter, Open-label, Randomized, Phase 2 Study of Venetoclax and Azacitidine Plus Cusatuzumab Versus Venetoclax and Azacitidine Alone in Newly Diagnosed AML Patients Who Are Not Candidates for Intensive Therapy is a PHASE2 clinical asset sponsored by OncoVerity, Inc. in Leukemia, Myeloid, Acute. SEO and diligence focus: Cusatuzumab, Venetoclax, Azacitidine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.